Skip to content
Open access

Protein design to broadly reprogram engineered T cell function

Aug 2026 · bioRxiv · 0 citations
Biology

TL;DR

OutLAST Regulators are designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence and are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enhanced cell and gene therapies.

Abstract

The efficacy of engineered T cell therapies in solid tumors remains limited by T cell dysfunction, driven by complex processes that cannot be easily manipulated via genetic knockouts or overexpression of individual genes. Protein design can create new biological functions that can rewire these consequential cell fate decisions. Here, we introduce OUTLAST Regulators, designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence. These proteins are capable of regulating diverse groups of proteins such as the NR4A family of pro-exhaustion transcription factors, E3 ligases Cbl-b and c-Cbl, and SOCS family proteins. Our designs markedly improve CAR-T and TCR-T performance in vitro and in vivo in stringent solid tumor preclinical models. OUTLAST Regulators are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enhanced cell and gene therapies.

Read PDF

Similar papers

Review Aug 2026

The landscape of genetic medicines for in vivo T cell reprogramming.

Key challenges related to the biodistribution, activation, and persistence of modified T cells are highlighted, with an emphasis on the potential of these strategies for treating not only blood cancers but also solid tumors, autoimmune diseases, and beyond.

Jens B. Simonsen, Viktor T. Lemgart, J. Kulkarni et al. · 1 citation
Review 2026

Manufacturing as biology: How T-cell processing shapes therapeutic outcomes.

This review underscores that optimizing T-cell therapy requires treating manufacturing not as a logistical necessity but as a controllable biological intervention, and a mechanistic understanding of how processing decisions program cellular behavior will enable the rational design of more potent, durable, and scalable...

Nikolai Przybylski, Qing-He Zeng, Xiao Huang · 0 citations
#gene editing Review Open access Aug 2026

Applications and Future Perspectives of CRISPR/Cas9 Gene Editing Technologies in CAR-T Cell Therapy

In general, CRISPR/Cas9-based engineering is a promising way of developing the next generation of precision cancer immunotherapy and is likely to be improved further in future through advancements in genome editing technology, delivery methods, and synthetic biology.

Meng-Ying Liu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.